Immune Response News and Research

RSS

Cancer patients on chemotherapy have lower immune response to COVID-19 vaccine, study finds

The COVID-19 pandemic has been an especially stressful time for cancer patients undergoing chemotherapy, which attacks not only the cancer, but also the immune cells needed to defend the body from infections.

2 Oct 2021

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral medicines for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.

1 Oct 2021

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

A promising study shows that a combination of two monoclonal antibodies effectively neutralized SARS-CoV-2 in monkeys and proved efficacious against newer variants of concern in vitro.

1 Oct 2021

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

A new study reported the persistence of immune responses over twelve months after natural infection.

1 Oct 2021

Study reveals a link between genital warts and the human leukocyte antigen system

New research presented today at the EADV 30th Congress reveals a link between genital warts and the human leukocyte antigen system - the part of the immune system which helps regulate immune responses.

1 Oct 2021

Similar viral load in vaccinated and unvaccinated individuals infected with SARS-CoV-2 Delta variant

Researchers evaluated Ct-values among distinct groups, namely, a) completely vaccinated and unvaccinated individuals and b) asymptomatic and symptomatic individuals at the time of testing.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Researchers develop nanoparticles delivering STING agonists for intravenous cancer immunotherapy

Cancer immunotherapy seeks to turn "cold" tumors into "hot" tumors––those that respond to immunotherapy––by awakening and enlisting the body's own immune system.

30 Sep 2021

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

A recent study conducted by researchers from the US aimed to measure the impact of severity of COVID-19 on memory B cell response and characterize changes in the memory B cell compartment during the period between recovery and five months after symptom onset. This study is available on the bioRxiv* preprint server.

30 Sep 2021

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

In a study published today in the American Journal of Transplantation, Johns Hopkins Medicine researchers say that children between the ages of 12 and 18 who have received solid organ transplants appear to mount a more robust immune response than their adult counterparts after a standard two-dose vaccination regimen against SARS-CoV-2, the virus that causes COVID-19.

30 Sep 2021

Study reveals how to improve overall immune response against virally driven cancers

Blocking the PD-1 inhibitory pathway within a subset of specialized T-cells may improve overall immune response against virally driven cancers, according to findings published in Nature.

30 Sep 2021

The applications of nanomaterials against viral disease

The application of nanomaterials in the diagnosis, prevention, and treatment of viral diseases is reviewed in detail, highlighting areas of significant progress or stagnation from the past few decades.

30 Sep 2021

Scientists describe SARS-CoV-2 uptake in tissue-resident human macrophages enhanced by virus-specific antibodies

Now, in a new news study posted to the bioRxiv* preprint server, researchers have successfully induced similar chronicity associated with SARS-CoV-2 infection in MISTRG6-hACE2 humanized mice.

29 Sep 2021

Scientists offers new hope for future treatment of sepsis

Sepsis, the body's life-threatening response to infection affecting about 1.7 million adults in the United States each year, can lead to multisystem organ failure with a high mortality rate.

29 Sep 2021

Long-held theory of cancer-induced immune suppression requires revision, study says

Many cancers produce an enzyme called IDO that suppresses immune system activity, but the long-held hypothesis of how this mechanism operates requires revision, according to a study published in Clinical Cancer Research.

29 Sep 2021

Study finds correlation between neutralizing antibody titer and reported vaccine efficacy

An observational study compares immune responses against three vaccines.

29 Sep 2021

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Scientists are reporting promising results in the early stages of a clinical trial designed to gauge the feasibility of a new type of treatment for people with acute kidney disease.

28 Sep 2021

Study shows Delta variant is main variant causing vaccine breakthrough COVID-19 infections, irrespective of manufacturer

In a recent study, researchers from Texas assessed the incidence of new SARS-CoV-2 variants of concern in the communities in Dallas-Fort Worth (DFW).

28 Sep 2021

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that SAB-185, a novel polyclonal antibody therapy, has demonstrated safety and efficacy in phase 2 that meet the criteria for graduation to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).

28 Sep 2021

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

A new study discusses the utility of a third booster dose in patients with myelofibrosis.

27 Sep 2021

Immune Response News and Research

Cancer patients on chemotherapy have lower immune response to COVID-19 vaccine, study finds

WHO's new List of Essential Medicines prioritizes access to diabetes and cancer treatments

Two-mAb cocktail prevents SARS-CoV-2 infection, study suggests

Persistence of humoral immune response in SARS-CoV-2 convalescent individuals a year after infection

Study reveals a link between genital warts and the human leukocyte antigen system

Similar viral load in vaccinated and unvaccinated individuals infected with SARS-CoV-2 Delta variant

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Researchers develop nanoparticles delivering STING agonists for intravenous cancer immunotherapy

Non-severe COVID-19 may elicit more durable memory B cell response than severe COVID-19

Pediatric transplant recipients mount a more robust immune response after two COVID-19 vaccine doses

Study reveals how to improve overall immune response against virally driven cancers

The applications of nanomaterials against viral disease

Scientists describe SARS-CoV-2 uptake in tissue-resident human macrophages enhanced by virus-specific antibodies

Scientists offers new hope for future treatment of sepsis

Long-held theory of cancer-induced immune suppression requires revision, study says

Study finds correlation between neutralizing antibody titer and reported vaccine efficacy

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Study shows Delta variant is main variant causing vaccine breakthrough COVID-19 infections, irrespective of manufacturer

Novel polyclonal antibody therapy meets the criteria for graduation to phase 3 in ACTIV-2 trial

Third COVID-19 mRNA vaccine booster dose indicated for myelofibrosis patients

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News